Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 9/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1919313 | 1.00 | GSR (0.42) | GSRCA2ALDH1A1MAPTCYP2C19 | |
| SCHEMBL636731 | 1.00 | GSR (0.42) | GSRCA2ALDH1A1MAPTCYP2C19 | |
| SCHEMBL1920541 | 0.98 | GSR (0.43) | GSRCA2ALDH1A1MAPTCYP2C19 | |
| SCHEMBL3494197 | 0.84 | GSR (0.39) | GSRCA2ALDH1A1MAPTGABRR1 | |
| SCHEMBL3490659 | 0.84 | GSR (0.39) | GSRCA2ALDH1A1MAPTGABRR1 | |
| SCHEMBL2468716 | 0.84 | GSR (0.39) | GSRCA2ALDH1A1MAPTGABRR1 | |
| SCHEMBL2009656 | 0.81 | GSR (0.38) | GSRCA2 | |
| SCHEMBL1919263 | 0.81 | GSR (0.54) | GSRCA2ALDH1A1MAPT | |
| SCHEMBL636135 | 0.81 | GSR (0.54) | GSRCA2ALDH1A1MAPT | |
| SCHEMBL10157707 | 0.81 | GSR (0.54) | GSRCA2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326652-B1 | NITRO DERIVATIVES OF FURASEMIDE AND THEIR USE AS DIURETICS | MERCK SHARP & DOHME (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8119806-B2 | Cicletanine derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100029678-A1 | DIURETICS | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029678-A1 | DIURETICS | NR3C2, REN, NR3C1 | GSR 1191/4885CA2 291/4885ALDH1A1 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.